Loading
DDR2 is a receptor that senses collagen; mutations in it occur in a small share of squamous lung cancers, and dasatinib inhibits it. This dossier gathers the 1 product (1 approved), 7 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Collagen binding through the discoidin domain triggers slow, sustained kinase activation, regulating cell adhesion, migration and matrix remodelling.
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Non-small-cell lung cancer | 3.8% | DDR2 kinase mutation, Sanger sequencing of squamous cell lung cancers and cell lines | Squamous histology only; mutant cell lines and one patient responded to dasatinib | doi.org |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
| Modality | Approved |
|---|---|
| Small molecule 1 |
| Trial | Setting | Result | Products | ||
|---|---|---|---|---|---|
| 3 | Active | A Phase III, Multi-center, Open-label, Randomized Study of Oral Asciminib Versus Investigator Selected TKI in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase | - | ||
| 3 | Completed | A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations | - | ||
READY NCT00744497 | 3 | Negative | Chemotherapy-naive metastatic castration-resistant prostate cancer with adequate organ function, stratified by ECOG performance status, bisphosphonate use and urinary N-telopeptide: docetaxel 75 mg/m2 every 3 weeks with prednisone 5 mg twice daily, plus dasatinib 100 mg once daily or placebo, with overall survival as the primary endpoint | Median overall survival 21.5 against 21.2 months (stratified hazard ratio 0.99, 95.5 percent confidence interval 0.87 to 1.13, p=0.90): no benefit. | |
DASISION NCT00481247 | 3 | Positive | Newly diagnosed chronic-phase chronic myeloid leukaemia: dasatinib 100 mg daily against imatinib 400 mg daily | Dasatinib produced higher confirmed complete cytogenetic and major molecular response rates at 12 months than imatinib, with no difference in five-year overall survival. | |
D-ALBA (GIMEMA LAL2116) NCT02744768 | 2 | Positive | Newly diagnosed Ph-positive ALL, adults of all ages: dasatinib induction followed by blinatumomab, no systemic chemotherapy | 18-month OS 95%, DFS 88%. | |
| 2 | Recruiting | Advanced solid tumours, multiple myeloma and B-cell lymphoma with a genomic alteration that an approved targeted drug addresses in another cancer: the drug is given off-label in a pragmatic basket with cohorts by drug and tumour type | Continuous cohort reporting: positive signals for pembrolizumab in high tumour mutational burden cancers and trastuzumab plus pertuzumab in ERBB2-amplified colorectal cancer; palbociclib in CDKN2A-altered lung cancer and several other matches were negative. | ||
| 2 | Recruiting | Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal Cancer | - |
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"DDR2 receptor kinase" OR ABSTRACT:"DDR2 receptor kinase" OR TITLE:"DDR2" OR ABSTRACT:"DDR2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DDR2 receptor kinase, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/ddr2.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/ddr2.json. Licence CC BY-NC 4.0.